ZDA
ROIV icon

Zweig-DiMenna Associates’s Roivant Sciences ROIV Stock Holding History

Zweig-DiMenna Associates’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-99,500
Closed -$1.18M – 101
2024
Q4 		$1.18M Buy
+99,500
New +$1.18M 0.09% 83

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Zweig-DiMenna Associates's ROIV Position: Q1 2025 in Review

Zweig-DiMenna Associates sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 99,500 shares — an estimated $1.18M sold.

Zweig-DiMenna Associates first reported a position in ROIV in Q4 2024 and held it in 1 quarter. The position peaked at $1.18M in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

  • Zweig-DiMenna Associates reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 99,500 Roivant Sciences shares in Q1 2025, an estimated $1.18M.
  • Zweig-DiMenna Associates first reported a position in Roivant Sciences in Q4 2024 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Roivant Sciences position peaked at $1.18M in Q4 2024.
  • 312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2025, filed 7 May 2025.